Enzyme News and Research

RSS

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from enhancing the immune system's ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists have been chosen to receive the 2014 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant.

19 May 2014

MetLife announces recipients of 2014 MetLife Foundation Awards for Medical Research

MetLife Foundation today announced the recipients of the 2014 MetLife Foundation Awards for Medical Research.

16 May 2014

OxThera granted new patents for treatment of hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the last year.

15 May 2014

SapC-DOPS technology: New way to image glioblastoma multiforme tumors

Just because you can't see something doesn't mean it's not there. Brain tumors are an extremely serious example of this and are not only difficult to treat-both adult and pediatric patients have a five-year survival rate of only 30 percent-but also have even been difficult to image, which could provide important information for deciding next steps in the treatment process.

15 May 2014

New technology has potential to make production of biotech medicines simpler

The final step in the production of a biotech medicine is finishing with the correct sugar structure. This step is essential for the efficacy of the medicine, but it also makes the production process very complex and expensive.

15 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Intensive insulin treatment improves survival for diabetic heart attack patients

Long-term follow-up of the DIGAMI 1 trial – a landmark study of type 2 diabetes in Sweden – shows that intensive insulin treatment prolonged life by more than 2 years in patients with diabetes after a heart attack, compared with standard treatment for diabetes, reports Dr Viveca Ritsinger from the Unit of Cardiology of the Department of Medicine, Karolinska Institute, Stockholm, Sweden and colleagues in The Lancet Diabetes & Endocrinology.

14 May 2014

SGK1 enzyme, asthma and cancer therapies: an interview with Dr. Jonathan D. Powell, Johns Hopkins Kimmel Cancer Center

SGK1 stands for serum/glucocorticoid-regulated kinase 1. SGK1 is a member of the AGC kinase family, which is a huge family of kinases.

13 May 2014

Researchers identify target molecules for development of new allergy drugs

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. Completed in a large-scale EU project, the lead author of the review article is Professor Ilkka Harvima of the University of Eastern Finland and Kuopio University Hospital.

13 May 2014

Researchers identify several target molecules suitable for development of new allergy drugs

13 May 2014

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

Dyadic International's total revenue for Q1 2014 up 20%

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, today announced financial results for the first quarter ended March 31, 2014.

8 May 2014

TSRI scientists create bacteria with expanded DNA code

Scientists at The Scripps Research Institute have engineered a bacterium whose genetic material includes an added pair of DNA “letters,” or bases, not found in nature. The cells of this unique bacterium can replicate the unnatural DNA bases more or less normally, for as long as the molecular building blocks are supplied.

8 May 2014

Enzyme News and Research

Existing pharmaceutical drugs may offer effective therapies against MERS

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

MetLife announces recipients of 2014 MetLife Foundation Awards for Medical Research

OxThera granted new patents for treatment of hyperoxaluria

SapC-DOPS technology: New way to image glioblastoma multiforme tumors

New technology has potential to make production of biotech medicines simpler

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Intensive insulin treatment improves survival for diabetic heart attack patients

SGK1 enzyme, asthma and cancer therapies: an interview with Dr. Jonathan D. Powell, Johns Hopkins Kimmel Cancer Center

Researchers identify target molecules for development of new allergy drugs

Researchers identify several target molecules suitable for development of new allergy drugs

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

Dyadic International's total revenue for Q1 2014 up 20%

TSRI scientists create bacteria with expanded DNA code

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Triple therapy shows promise for severe PAH

Rice University researchers find new possibilities for benign, 'tunable' virus

New study explores how bacterial pathogen Yersinia tries to outsmart immune cell responses

Biochemistry eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News